Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

@article{GonzlezMartn2005RandomizedPI,
  title={Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.},
  author={Antonio J Gonz{\'a}lez-Mart{\'i}n and Elpidio Calvo and Isabel Bover and M. J{\'o}se Rubio and {\`A}ngels Arcusa and Araceli Casado and Bego{\~n}a Ojeda and Carmen Bala{\~n}a and Eric Martinez and Agueda Herrero and Bruno Pardo and Encarna Adrover and Julio Rif{\'a} and Mar{\'i}a Jos{\'e} Godes and Amelia Moyano and Alberto Cervantes},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 5},
  pages={749-55}
}
BACKGROUND The aim of this study was to determine whether the response rate for the paclitaxel-carboplatin combination is superior to carboplatin alone in the treatment of patients with platinum-sensitive recurrent ovarian carcinoma. PATIENTS AND METHODS Patients with recurrent ovarian carcinoma, 6 months after treatment with a platinum-based regimen and with no more than two previous chemotherapy lines, were randomized to receive carboplatin area under the curve (AUC) 5 (arm A) or paclitaxel… CONTINUE READING
48 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Single Agent Carboplatin is the Treatment of Choice in Recurrent Potentially Platinum-Sensitive Epithelial Ovarian Cancer

  • M. Markman
  • ASCO Educational Book Alexandria, VA: ASCO
  • 2002
2 Excerpts

Similar Papers

Loading similar papers…